B7-H3 CAR T-cell treatment showed encouraging anti-tumor activity and manageable toxicity profile in pediatric relapsed/refractory solid tumors, including neuroblastoma in a phase I trial (NCT04483778) [190]. The gene discussed is CD276; the disease is neuroblastoma.